<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Nucl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Nucl Med</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</journal-title></journal-title-group><issn pub-type="ppub">0161-5505</issn><issn pub-type="epub">1535-5667</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11384506</article-id><article-id pub-id-type="pmcid-ver">PMC11384506.1</article-id><article-id pub-id-type="pmcaid">11384506</article-id><article-id pub-id-type="pmcaiid">11384506</article-id><article-id pub-id-type="manuscript-id">NIHMS2020525</article-id><article-id pub-id-type="pmid">25525184</article-id><article-id pub-id-type="doi">10.2967/jnumed.114.148106</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2020525</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2020525</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Whole-Body PET/CT Evaluation of Tumor Perfusion Using Generator-Based <sup>62</sup>Cu-Ethylglyoxal <italic toggle="yes">Bis</italic>(Thiosemicarbazonato)Copper(II): Validation by Direct Comparison to <sup>15</sup>O-Water in Metastatic Renal Cell Carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Fletcher</surname><given-names initials="JW">James W.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Logan</surname><given-names initials="TF">Theodore F.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eitel</surname><given-names initials="JA">Jacob A.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mathias</surname><given-names initials="CJ">Carla J.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ng</surname><given-names initials="Y">Yen</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lacy</surname><given-names initials="JL">Jeffrey L.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hutchins</surname><given-names initials="GD">Gary D.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Green</surname><given-names initials="MA">Mark A.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana</aff><aff id="A2"><label>2</label>The Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana</aff><aff id="A3"><label>3</label>Proportional Technologies, Inc., Houston, Texas</aff><author-notes><corresp id="CR1">For correspondence or reprints contact: James W. Fletcher, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 550 North University Ave., Rm. 0655A, Indianapolis, IN 46202. <email>jwfletch@iupui.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2014</year></pub-date><volume>56</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">470392</issue-id><fpage>56</fpage><lpage>62</lpage><pub-history><event event-type="nihms-submitted"><date><day>03</day><month>09</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>10</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>10</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-12 09:25:14.160"><day>12</day><month>09</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2020525.pdf"/><abstract id="ABS1"><p id="P1">This study was undertaken to demonstrate the feasibility of whole-body <sup>62</sup>Cu-ethylglyoxal <italic toggle="yes">bis</italic>(thiosemicarbazonato)copper(II) (<sup>62</sup>Cu-ETS) PET/CT tumor perfusion imaging in patients with metastatic renal carcinoma and to validate <sup>62</sup>Cu-ETS as a quantitative marker of tumor perfusion by direct comparison with <sup>15</sup>O-water perfusion imaging.</p><sec id="S1"><title>Methods:</title><p id="P2">PET/CT imaging of 10 subjects with stage IV renal cell cancer was performed after intravenous administration of <sup>15</sup>O-water (10-min dynamic list-mode study) with the heart and at least 1 tumor in the PET field of view, followed 10 min later by intravenous <sup>62</sup>Cu-ETS (6-min list-mode study). Whole-body <sup>62</sup>Cu imaging was then performed from 6 to 20 min at 2&#8211;3 min/bed position. Blood flow (<italic toggle="yes">K</italic><sub>1</sub>) was quantified with both agents for normal and malignant tissues in the 21.7-cm dynamic field of view. The required arterial input functions were derived from the left atrium and, in the case of <sup>62</sup>Cu-ETS, corrected for partial decomposition of the agent by blood with data from an in vitro analysis using a sample of each patient&#8217;s blood. This imaging protocol was repeated at an interval of 3&#8211;4 wk after initiation of a standard clinical treatment course of the antiangiogenic agent sunitinib.</p></sec><sec id="S2"><title>Results:</title><p id="P3">All subjects received the scheduled <sup>62</sup>Cu-ETS doses for the dynamic and subsequent whole-body PET/CT scans, but technical issues resulted in no baseline <sup>15</sup>O-water data for 2 subjects. Direct comparisons of the perfusion estimates for normal tissues and tumor metastases were made in 18 paired baseline and treatment studies (10 subjects; 8 baseline studies, 10 repeated studies during treatment). There was an excellent correlation between the blood flow estimates made with <sup>62</sup>Cu-ETS and <sup>15</sup>O-water for normal tissues (muscle, thyroid, myocardium) and malignant lesions (pulmonary nodules, bone lesions); the regression line was <italic toggle="yes">y</italic> = 0.85<italic toggle="yes">x</italic> + 0.15, <italic toggle="yes">R</italic><sup>2</sup> = 0.83, for the 88 regions analyzed.</p></sec><sec id="S3"><title>Conclusion:</title><p id="P4"><sup>62</sup>Cu-ETS provided high-quality whole-body PET/CT images, and <sup>62</sup>Cu-ETS measures of blood flow were highly and linearly correlated with <sup>15</sup>O-water&#8211;derived <italic toggle="yes">K</italic><sub>1</sub> values (mL<sup>&#8722;1</sup>&#183;min<sup>&#8722;1</sup>&#183;g). This tracer is suitable for use as a PET tracer of tumor perfusion in patients with metastatic renal cell carcinoma.</p></sec></abstract><kwd-group><kwd>tumor perfusion</kwd><kwd><sup>62</sup>Cu PET</kwd><kwd><sup>62</sup>Cu-ETS [ethylglyoxal <italic toggle="yes">bis</italic>(thiosemicarbazonato)copper(II)]</kwd><kwd><sup>15</sup>O-water</kwd><kwd>renal cell carcinoma</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>